BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Ghiringhelli F, Guiu B, Chauffert B, Ladoire S. Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study. World J Gastroenterol 2009; 15(34): 4278-4283 [PMID: 19750570 DOI: 10.3748/wjg.15.4278]
URL: https://www.wjgnet.com/1007-9327/full/v15/i34/4278.htm
Number Citing Articles
1
Melissa Hu, Oleksandr Ekshyyan, Lilantha Herman Ferdinandez, Xiaohua Rong, Gloria Caldito, Cherie-Ann O. Nathan. Efficacy and comparative effectiveness of sirolimus as an anticancer drugThe Laryngoscope 2011; 121(5): 978 doi: 10.1002/lary.21724
2
Sarah Jannier, Véronique Kemmel, Consuelo Sebastia Sancho, Agathe Chammas, Amelia-Naomie Sabo, Erwan Pencreach, Françoise Farace, Marie Pierre Chenard, Benoit Lhermitte, Birgit Geoerger, Isabelle Aerts, Didier Frappaz, Pierre Leblond, Nicolas André, Stephane Ducassou, Nadège Corradini, Anne Isabelle Bertozzi, Eric Guérin, Florence Vincent, Michel Velten, Natacha Entz-Werle. SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory CancersCancers 2020; 12(10): 3051 doi: 10.3390/cancers12103051